You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石药业(02616.HK)与Blueprint启动治疗肝细胞癌患者的Ib/II期临床试验
阿思达克 01-07 09:57

基石药业(02616.HK)公布,公司与Blueprint Medicines,即一家专注於探索具有特定基因特徵的癌症、罕见病及癌症免疫疗法的精准治疗的公司,共同宣布fisogatinib(一款对致癌驱动因数具有高选择性的药物)联合CS1001治疗局部晚期或转移性肝细胞癌(HCC)的Ib/II期试验已完成首例患者给药,研究将在中国的多个临床研究中心开展。

公司指,此项试验将评估靶向治疗和癌症免疫治疗联合在局部晚期和转移性HCC患者中增强抗肿瘤活性的潜力。fisogatinib是由BlueprintMedicines开发的一款在研的强效、高选择性成纤维细胞生长因数受体-4(「FGFR4」)抑制剂,用於治疗FGFR4驱动的晚期HCC。CS1001是一款由基石药业开发的、针对多个癌种的在研抗PD-L1单克隆抗体。临床前研究表明,fisogatinib可以刺激T细胞浸润到肿瘤微环境中,这提示fisogatinib联合抗PD-L1抑制剂将有可能在FGFR4驱动的晚期HCC患者中展现出更强的疗效。

公司已与BlueprintMedicines达成独家合作及授权协议,获得了包括fisogatinib在内的三款候选药物在中国大陆、香港、澳门及台湾的开发与商业化权利。Blueprint Medicines保留在世界其他地区开发及商业化这三款候选药物的权利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account